Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 1 A, 2008, Pages 55-68

  Bishop, Jeffrey R ^a   Pavuluri, Mani N ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Adolescents; Bipolar disorder; Children; Risperidone; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; BENZATROPINE; CARBAMAZEPINE; CLOZAPINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; PLACEBO; PROLACTIN; QUETIAPINE; RISPERIDONE; SEROTONIN 2A ANTAGONIST; VALPROATE SEMISODIUM; ZIPRASIDONE;

ADOLESCENT; AKATHISIA; AMENORRHEA; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; AUTISM; BIPOLAR DISORDER; BLURRED VISION; BREAST TENDERNESS; BRIEF PSYCHIATRIC RATING SCALE; CHILD; CHILL; CLINICAL EFFECTIVENESS; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONDUCT DISORDER; CONSTIPATION; COORDINATION DISORDER; DEPRESSION; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; DYSTONIA; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; HEADACHE; HIRSUTISM; HORMONE BLOOD LEVEL; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; HYPOGONADISM; INCREASED APPETITE; LANGUAGE DISABILITY; LIBIDO; LOW DRUG DOSE; MENSTRUAL IRREGULARITY; MICTURITION DISORDER; MUSCULOSKELETAL PAIN; NAUSEA; NERVOUSNESS; OBSESSIVE COMPULSIVE DISORDER; OPPOSITIONAL DEFIANT DISORDER; OROFACIAL DYSKINESIA; ORTHOSTATIC HYPOTENSION; PATIENT MONITORING; POLYDIPSIA; POLYURIA; POSITIVE AND NEGATIVE SYNDROME SCALE; POSTTRAUMATIC STRESS DISORDER; PROLACTIN BLOOD LEVEL; RESTLESSNESS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SPERMATOGENESIS; STANDING; SWEAT; TARDIVE DYSKINESIA; THIRST; WEAKNESS; WEIGHT GAIN; XEROSTOMIA;

EID: 41549114562     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. ADA, APA. 2004. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27:596-601.
2. Aman MG, De Smedt G, Derivan A, et al. 2002. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry, 159:1337-46.
3. Armenteros JL, Whitaker AH, Welikson M, et al. 1997. Risperidone in adolescents with schizophrenia: an open pilot study. J Am Acad Child Adolesc Psychiatry, 36:694-700.
4. Biederman J, Mick E, Hammerness P, et al. 2005a. Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol Psychiatry, 58:589-94.
5. Biederman J, Mick E, Wozniak J, et al. 2005b. An open-label trial of risperidone in children and adolescents with bipolar disorder. J Child Adolese Psychopharmacol, 15:311-7.
6. Correll CU. 2007. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry, 46:687-700.
7. Dickson RA, Glazer WM. 1999. Neuroleptic-induced hyperprolactinemia. Schizophr Res, 35(Suppl):S75-86.
8. Dunbar F, Kusumakar V, Daneman D, et al. 2004. Growth and sexual maturation during long-term treatment with risperidone. Am J Psychiatry, 161:918-20.
9. Findling RL, Kusumakar V, Daneman D, et al. 2003. Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry, 64:1362-9.
10. Findling RL, McNamara NK, Branicky LA, et al. 2000. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolese Psychiatry, 39:509-16.
11. Frazier JA, Meyer MC, Biederman J, et al. 1999. Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. J Am Acad Child Adolesc Psychiatry, 38:960-5.
12. Gaffney GR, Perry, PJ, Lund BC, et al. 2002. Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. J Am Acad Child Adolesc Psychiatry, 41:330-6.
13. Gardner DM, Baldessarini RJ, Waraich P. 2005. Modern antipsychotic drugs: a critical overview. CMAJ, 172:1703-11.
14. Gothelf D, Apter A, Reidman J, et al. 2003. Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. J Neural Transm, 110:545-60.
15. Haas M, Unis AS, Copehhaver M, et al. 2007. Efficacy and Safety of Risperidone in Adolescents with Schizophrenia. American Psychiatric Association Annual Meeting:221.
16. Howes O, Smith, S. 2002. Hyperprolactinaemia caused by antipsychotic drugs. Endocrine antipsychotic side effects must be systemically assessed. BMJ, 324:1278.
17. Kinon BJ, Gilmore JA, Liu H, et al. 2003. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology, 28(Suppl 2):69-82.
18. Kowatch RA, DelBello MP. 2005. Pharmacotherapy of children and adolescents with bipolar disorder. Psychiatr Clin North Am, 28:385-97.
19. Lamb E. 2007. Top 200 Prescription Drugs of 2006. Pharmacy Times.
20. Malone RP, Maislin G, Choudhury MS, et al. 2002. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry, 41:140-7.
21. Marsden CD, Jenner P. 1980. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med, 10:55-72.
22. Masi G, Cosenza A, Mucci M, et al. 2003. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry, 64:1039-47.
23. Matsui-Sakata A, Ohtani H, Sawada Y. 2005. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet, 20:368-78.
24. McCracken JT, McGough J, Shah B, et al. 2002. Risperidone in children with autism and serious behavioral problems. N Engl J Med, 347:314-21.
25. McDougle CJ, Holmes JP, Bronson MR et al. 1997. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry, 36:685-93.
26. Miller AL, Hall CS, Buchanan RW, et al. 2004. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry, 65:500-8.
27. Mozes T, Ebert T, Michal SE, et al. 2006. An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia. J Child Adolesc Psychopharmacol, 16:393-403.
28. Ogden CL, Yanovski SZ, Carroll MD, et al. 2007. The epidemiology of obesity. Gastroenterology, 132:2087-102.
29. Patel NC, Crismon ML, Hoagwood K, et al. 2005. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry, 44:548-56.
30. Pavuluri MN, Henry DB, Carbray JA, et al. 2004a. Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania. J Affect Disord, 82(Suppl 1):S103-11.
31. Pavuluri MN, Henry DB, Devineni B, et al. 2004b. A pharmacotherapy algorithm for stabilization and maintenance of pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry, 43:859-67.
32. Petty RG. 1999. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res, 35(Supp 1):S67-73.
33. Ratzoni G, Gothelf D, Brand-Gothelf A, et al. 2002. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry, 41:337-43.
34. Saito E, Correll CU, Gallelli K, et al. 2004. A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol, 14:350-8.
35. Saxena K, Chang K, Steiner H. 2006. Treatment of aggression with risperidone in children and adolescents with bipolar disorder: a case series. Bipolar Disord, 8:405-10.
36. Sikich L, Hamer RM, Bashford RA, et al. 2004. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology, 29:133-45.
37. Snyder R, Turgay A, Aman M, et al. 2002. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry, 41:1026-36.
38. van Bruggen J, Tijssen J, Dingemans P, et al. 2003. Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia. Int Clin Psychopharmacol, 18:341-6.
39. Zalsman G, Carmon E, Martin A, et al. 2003. Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. J Child Adolesc Psychopharmacol, 13:319-27.